Veloxis Pharmaceuticals announced that LCP-Tacro successfully demonstrated non-inferiority compared to tacrolimus (Prograf®; Astellas Pharma) in its Phase III clinical trial, Study 3002.
The Phase III randomized, double-blind and double-dummy study in 543 de novo kidney transplant recipients, with Prograf as the comparator, met its primary efficacy and primary safety endpoints.
The study was conducted under a Special Protocol Agreement with the FDA and the results are considered pivotal for the planned U.S. regulatory filing expected to occur in the second half of 2013.
"The results observed in this clinical trial suggest that new kidney transplant patients can begin with a regimen of once-daily LCP-Tacro™ rather than twice-daily as required with current tacrolimus products, without compromising efficacy and tolerability," said Dr. Suphamai Bunnapradist, M.D., Professor of Medicine and Director of Kidney Transplant Research at the Ronald Reagan Medical Center and David Geffen School of Medicine at UCLA, California, USA. "This is important because once-daily dosing should be beneficial for kidney transplant patients who are on life-long complex therapy."
LCP-Tacro demonstrated non-inferiority to Prograf in preventing kidney transplant rejection, including in the early post-transplant period
The primary endpoint of the study was a composite endpoint of treatment failure (biopsy-proven acute rejection or BPAR, graft failure, loss to follow up or death) that was evaluated after a 12-month treatment period to demonstrate the non-inferiority of LCP-Tacro compared to Prograf.
The treatment failure rate for LCP-Tacro was 18.3% compared to 19.6% for Prograf, well within the 10% pre-specified non-inferiority margin.
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- How A Former Naturopath Can Help Unravel The Trickery of Alternative Medicine
- Tidal Disruption Event: Black Hole Eats Star, Beams Signal To Earth
- Dear California: Why Is Farming Science A Bad Thing Again?
- Psychiatric Diagnoses Not Valid For African-Americans, Says Sociologist
- 5 Laws About Corpses That May Spook You
- 9,000 Years: Origin Of Farmed Rice Gets Pushed Back
- Dengue Virus Exposure May Amplify Zika Infection
- "I've known a few people with fake celiacs and I've known a few real celiacs. You can find a lot..."
- "This is an interesting set of lecture notes by Cranmer from TASI, https://sites.google.com/a/colorado..."
- "Criminal - Clinton Pathological Liar - Clinton Narcissist Egomaniac - Trump - Clinton Lied when..."
- "The only sensible numbers are zero, one, and infinity. Government works the same way. Zero - true..."
- "Hi John,I'll let your comment live out of respect for the effort you put in writing it, but I disagree..."
- ACSH Applauds Media Awareness of the Fentanyl Crisis
- Counting Bites Examined, to Help Decrease Food Intake
- The Safe And Unsafe Nutty Treats For Your Pup
- Mr. Potato Head Needs a New Warning Label!
- Shark Finning is Banned in the US; Banning Trade in Fins May Be Next
- Move Over Zika, It’s Yellow Fever’s Turn
- Should I stay or should I go?
- New cancer immunotherapy drugs linked to arthritis in some patients
- Simulations foresee hordes of colliding black holes in LIGO's future
- Analysis of genetic repeats suggests role for DNA instability in schizophrenia
- Analysis of media reporting reveals new information about snakebites and how and when they occur